SEGLUROMET 2.5 mg/1

Segluromet 2.5 mg/1 combines ertugliflozin and metformin hydrochloride for managing type 2 diabetes. This oral medication supports blood sugar control as part of a broader treatment plan.

Segluromet 2.5 mg/1 is used to help manage type 2 diabetes by improving blood sugar levels. It combines two active ingredients, ertugliflozin and metformin hydrochloride, which work together to support glucose regulation. This medication is typically prescribed alongside diet and exercise to enhance overall diabetes management.

Common effects of Segluromet 2.5 mg/1 may include gastrointestinal discomfort, such as nausea or diarrhea. Some users might experience urinary tract infections or low blood sugar, especially when combined with other diabetes medications. Individual responses can vary, and not everyone will experience these effects.

Segluromet 2.5 mg/1 should be handled with care, particularly for those with kidney issues or a history of lactic acidosis. It is important to follow healthcare provider instructions and monitor blood sugar levels regularly. Always inform your healthcare provider about any existing medical conditions or other medications you are taking.

Segluromet 2.5 mg/1 may interact with certain medications, including diuretics, blood pressure drugs, and other diabetes treatments. Alcohol consumption should be avoided as it can increase the risk of lactic acidosis. Always consult a healthcare provider before starting or stopping any medication.